A double-blind, placebo-controlled evaluation of the safety and efficacy of memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients with persistent residual symptoms.

Trial Profile

A double-blind, placebo-controlled evaluation of the safety and efficacy of memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients with persistent residual symptoms.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Mar 2012

At a glance

  • Drugs Memantine (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Mar 2012 Actual end date (Sep 2005) added as reported by ClinicalTrials.gov.
    • 09 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top